Juniper

Juniper is a deep-tech venture capital firm that invests at the early stage in biotechnology companies operating outside conventional pharmaceutical applications. The firm writes early checks into category-creating companies enabled by advances in biology, engineering, and computation, and frames its mandate around what it calls the Bioindustrial Revolution - the application of engineered biology to industrial production, food systems, agriculture, mining, manufacturing, and conservation.

Its technical remit is broad within that thesis. Areas of interest include engineered biology and biomanufacturing, microbial mineral extraction, plant-cell fermentation, natural colorants, robotics for automating biological work, and DNA data storage. Portfolio patterns point to companies translating laboratory biology into industrial processes and materials rather than therapeutics.

On approach, Juniper partners closely with technical founders and with other early-stage investors, and positions itself as a source of scientific and technical understanding alongside capital. The firm states an intention to help catalyse follow-on funding for its companies. Fund size, founding year, team size, and geographic presence are not disclosed.